{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:52:34Z","timestamp":1793674354393,"version":"4.5.1"},"reference-count":157,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP24fk0210149"],"award-info":[{"award-number":["JP24fk0210149"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP24fk0210154"],"award-info":[{"award-number":["JP24fk0210154"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP24fk0210128"],"award-info":[{"award-number":["JP24fk0210128"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP24fk0210141"],"award-info":[{"award-number":["JP24fk0210141"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP24K11119"],"award-info":[{"award-number":["JP24K11119"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JPMH23HC2002"],"award-info":[{"award-number":["JPMH23HC2002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS KAKENHI","award":["JP24fk0210149"],"award-info":[{"award-number":["JP24fk0210149"]}]},{"name":"JSPS KAKENHI","award":["JP24fk0210154"],"award-info":[{"award-number":["JP24fk0210154"]}]},{"name":"JSPS KAKENHI","award":["JP24fk0210128"],"award-info":[{"award-number":["JP24fk0210128"]}]},{"name":"JSPS KAKENHI","award":["JP24fk0210141"],"award-info":[{"award-number":["JP24fk0210141"]}]},{"name":"JSPS KAKENHI","award":["JP24K11119"],"award-info":[{"award-number":["JP24K11119"]}]},{"name":"JSPS KAKENHI","award":["JPMH23HC2002"],"award-info":[{"award-number":["JPMH23HC2002"]}]},{"name":"MHLW Program for Basic and Clinical Research on Hepatitis Program","award":["JP24fk0210149"],"award-info":[{"award-number":["JP24fk0210149"]}]},{"name":"MHLW Program for Basic and Clinical Research on Hepatitis Program","award":["JP24fk0210154"],"award-info":[{"award-number":["JP24fk0210154"]}]},{"name":"MHLW Program for Basic and Clinical Research on Hepatitis Program","award":["JP24fk0210128"],"award-info":[{"award-number":["JP24fk0210128"]}]},{"name":"MHLW Program for Basic and Clinical Research on Hepatitis Program","award":["JP24fk0210141"],"award-info":[{"award-number":["JP24fk0210141"]}]},{"name":"MHLW Program for Basic and Clinical Research on Hepatitis Program","award":["JP24K11119"],"award-info":[{"award-number":["JP24K11119"]}]},{"name":"MHLW Program for Basic and Clinical Research on Hepatitis Program","award":["JPMH23HC2002"],"award-info":[{"award-number":["JPMH23HC2002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer deaths worldwide. The etiology of HCC has now dramatically changed from viral hepatitis to metabolic dysfunction-associated steatotic liver disease (MASLD). The main pathogenesis of MASLD-related HCC is the hepatic lipid accumulation of hepatocytes, which causes chronic inflammation and the subsequent progression of hepatic fibrosis. Chronic hepatic inflammation generates oxidative stress and DNA damage in hepatocytes, which contribute to genomic instability, resulting in the development of HCC. Several metabolic and molecular pathways are also linked to chronic inflammation and HCC in MASLD. In particular, the MAPK and PI3K-Akt-mTOR pathways are upregulated in MASLD, promoting the survival and proliferation of HCC cells. In addition, MASLD has been reported to enhance the development of HCC in patients with chronic viral hepatitis infection. Although there is no approved medication for MASLD besides resmetirom in the USA, there are some preventive strategies for the onset and progression of HCC. Sodium-glucose cotransporter-2 (SGLT2) inhibitor, a class of medications, has been reported to exert anti-tumor effects on HCC by regulating metabolic reprogramming. Moreover, CD34-positive cell transplantation improves hepatic fibrosis by promoting intrahepatic angiogenesis and supplying various growth factors. Furthermore, exercise improves MASLD through an increase in energy consumption as well as changes in chemokines and myokines. In this review, we summarize the recent progress made in the pathogenic mechanisms of MASLD-associated HCC. Furthermore, we introduced new therapeutic strategies for preventing the development of HCC based on the pathogenesis of MASLD.<\/jats:p>","DOI":"10.3390\/cells14060428","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:53:00Z","timestamp":1741848780000},"page":"428","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0954-1191","authenticated-orcid":false,"given":"Toru","family":"Nakamura","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan"},{"name":"Liver Cancer Research Division, Research Center for Innovative Cancer Therapy, Kurume University, 67 Asahi-Machi, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3183-1200","authenticated-orcid":false,"given":"Atsutaka","family":"Masuda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan"},{"name":"Liver Cancer Research Division, Research Center for Innovative Cancer Therapy, Kurume University, 67 Asahi-Machi, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nakano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan"},{"name":"Liver Cancer Research Division, Research Center for Innovative Cancer Therapy, Kurume University, 67 Asahi-Machi, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2017-7973","authenticated-orcid":false,"given":"Keisuke","family":"Amano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan"},{"name":"Fukuoka Consulting and Support Center for Liver Diseases, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-3149","authenticated-orcid":false,"given":"Tomoya","family":"Sano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan"},{"name":"Fukuoka Consulting and Support Center for Liver Diseases, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3375-180X","authenticated-orcid":false,"given":"Masahito","family":"Nakano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7064-4325","authenticated-orcid":false,"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan"},{"name":"Liver Cancer Research Division, Research Center for Innovative Cancer Therapy, Kurume University, 67 Asahi-Machi, Kurume 830-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00535-020-01748-x","article-title":"The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan","volume":"56","author":"Enomoto","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/hepr.14047","article-title":"Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021","volume":"54","author":"Enomoto","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00535-018-1532-5","article-title":"A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011\u20132015 update","volume":"54","author":"Tateishi","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Nakano, M., Yatsuhashi, H., Bekki, S., Takami, Y., Tanaka, Y., Yoshimaru, Y., Honda, K., Komorizono, Y., Harada, M., and Shibata, M. (2022). Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-05444-z"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00535-020-01754-z","article-title":"Hepatocellular carcinoma development in diabetic patients: A nationwide survey in Japan","volume":"56","author":"Tateishi","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/hepr.14124","article-title":"Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma","volume":"55","author":"Sasaki","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/hepr.14049","article-title":"Combined effect of histological findings and diabetes mellitus on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease","volume":"54","author":"Shiomi","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/hepr.14020","article-title":"Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U\/L, exercise habits, and metabolic dysfunction-associated steatotic liver disease","volume":"54","author":"Nakano","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/hepr.13436","article-title":"Profiles of advanced hepatic fibrosis evaluated by FIB-4 index and shear wave elastography in health checkup examinees","volume":"50","author":"Yamamura","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101172","DOI":"10.1016\/j.jhepr.2024.101172","article-title":"ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population","volume":"6","author":"Mannisto","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.jhep.2023.07.031","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD","volume":"80","author":"De","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/j.jhep.2023.07.007","article-title":"A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank","volume":"80","author":"Schneider","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jhep.2022.08.015","article-title":"Non-invasive tests for evaluating treatment response in NAFLD","volume":"78","author":"Bantel","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jhep.2023.08.008","article-title":"Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study","volume":"79","author":"Simon","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events","volume":"76","author":"Boursier","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jhep.2019.04.020","article-title":"New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD","volume":"71","author":"Boursier","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/hepr.13738","article-title":"Atherosclerotic cardiovascular disease in non-metabolic nonalcoholic fatty liver disease","volume":"52","author":"Tsutsumi","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.jhep.2023.12.030","article-title":"Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia","volume":"80","author":"Nakano","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","article-title":"Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"80","author":"Ratziu","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Cales, P., Canivet, C.M., Costentin, C., Lannes, A., Oberti, F., Fouchard, I., Hunault, G., de Ledinghen, V., and Boursier, J. (J. Hepatol., 2024). A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD, J. Hepatol., in press.","DOI":"10.1016\/j.jhep.2024.11.049"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/apt.17995","article-title":"Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan","volume":"59","author":"Tsutsumi","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3350\/cmh.2024.0157","article-title":"Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia","volume":"30","author":"Suzuki","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/j.jhep.2023.12.004","article-title":"Changing from NAFLD to MASLD: Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD","volume":"80","author":"Suzuki","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3350\/cmh.2023.0557","article-title":"Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab\/bevacizumab treatment between NAFLD and MASLD","volume":"30","author":"Suzuki","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3350\/cmh.2023.0515","article-title":"Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study","volume":"30","author":"Iwaki","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.jhep.2024.02.010","article-title":"Changing from NAFLD to MASLD: The implications for health-related quality of life data","volume":"80","author":"Hashida","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MEG.0000000000002895","article-title":"Fast score is associated with patient-reported outcomes in patients with metabolic dysfunction-associated steatotic liver disease","volume":"37","author":"Hashida","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3350\/cmh.2024.0233","article-title":"Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia","volume":"30","author":"Fukunaga","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3350\/cmh.2023.0437","article-title":"Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD","volume":"30","author":"Fukunaga","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2445525","DOI":"10.1001\/jamanetworkopen.2024.45525","article-title":"Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040","volume":"7","author":"Qiu","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","article-title":"Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification","volume":"149","author":"Fisher","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"ref_36","first-page":"1635","article-title":"Cell cycle regulators and human hepatocarcinogenesis","volume":"45","author":"Hui","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3748\/wjg.v25.i19.2279","article-title":"Mechanisms of hepatocellular carcinoma progression","volume":"25","author":"Ogunwobi","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Xu, W., Nie, C., Lv, H., Chen, B., Wang, J., Wang, S., Zhao, J., He, Y., and Chen, X. (2022). Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1010554"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"155937","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/apt.17930","article-title":"Pathogenesis of MASLD and MASH\u2014Role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2024.06.016","article-title":"Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation","volume":"81","author":"Taru","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/1878-0261.13685","article-title":"MASH as an emerging cause of hepatocellular carcinoma: Current knowledge and future perspectives","volume":"19","author":"Karin","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"26087","DOI":"10.3390\/ijms161125942","article-title":"The Role of Oxidative Stress and Antioxidants in Liver Diseases","volume":"16","author":"Li","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Allameh, A., Niayesh-Mehr, R., Aliarab, A., Sebastiani, G., and Pantopoulos, K. (2023). Oxidative Stress in Liver Pathophysiology and Disease. Antioxidants, 12.","DOI":"10.3390\/antiox12091653"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lu, Y., Xu, X., Wu, J., Ji, L., Huang, H., and Chen, M. (2024). Association between neutrophil-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in the US population: A nationally representative cross-sectional study using NHANES data from 2017 to 2020. BMC Gastroenterol., 24.","DOI":"10.1186\/s12876-024-03394-6"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1089\/ars.2007.1993","article-title":"Reactive nitrogen species: Molecular mechanisms and potential significance in health and disease","volume":"11","author":"Martinez","year":"2009","journal-title":"Antioxid. Redox Signal"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Li, Z., Wang, S., Xu, Q., Su, X., Wang, Y., Wang, L., and Zhang, Y. (2024). The double roles of T cell-mediated immune response in the progression of MASLD. Biomed. Pharmacother., 173.","DOI":"10.1016\/j.biopha.2024.116333"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities","volume":"18","author":"Wen","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Papadopoulos, G., Giannousi, E., Avdi, A.P., Velliou, R.I., Nikolakopoulou, P., and Chatzigeorgiou, A. (2024). Tau cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1343806"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: Pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Liu, B., Deng, X., Jiang, Q., Li, G., Zhang, J., Zhang, N., Xin, S., and Xu, K. (2020). Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS\/P38\/Nrf2 axis and PI3K\/AKT\/mTOR pathway in macrophages. Biomed. Pharmacother., 125.","DOI":"10.1016\/j.biopha.2020.109895"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sun, C., Zhang, J., Hou, J., Hui, M., Qi, H., Lei, T., Zhang, X., Zhao, L., and Du, H. (2023). Induction of autophagy via the PI3K\/Akt\/mTOR signaling pathway by Pueraria flavonoids improves non-alcoholic fatty liver disease in obese mice. Biomed. Pharmacother., 157.","DOI":"10.1016\/j.biopha.2022.114005"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.acr.2020.10.002","article-title":"Signaling pathways in hepatocellular carcinoma","volume":"149","author":"Villanueva","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2024.08.029","article-title":"Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression","volume":"82","author":"Xu","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1038\/s41467-024-53733-0","article-title":"PTPRK regulates glycolysis and de novo lipogenesis to promote hepatocyte metabolic reprogramming in obesity","volume":"15","author":"Gilglioni","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","article-title":"Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: From bench to bedside","volume":"13","author":"Yin","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jvh.13412","article-title":"The case for simplifying and using absolute targets for viral hepatitis elimination goals","volume":"28","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","article-title":"Hepatitis B therapy","volume":"8","author":"Kwon","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/17474124.2014.909724","article-title":"Current developments in nucleoside\/nucleotide analogues for hepatitis B","volume":"8","author":"Lo","year":"2014","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wong, G.L., and Lemoine, M. (J. Hepatol., 2024). The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines, J. Hepatol., in press.","DOI":"10.1016\/j.jhep.2024.12.004"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s00535-018-1493-8","article-title":"The \u201creal-world\u201d efficacy and safety of DAAs for the treatment of HCV patients throughout Japan","volume":"53","author":"Maekawa","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-018-1520-9","article-title":"Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures","volume":"54","author":"Osawa","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","article-title":"Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: Two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)","volume":"5","author":"Wei","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.cgh.2024.01.045","article-title":"Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC","volume":"22","author":"Lee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e37990","DOI":"10.1016\/j.heliyon.2024.e37990","article-title":"Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma","volume":"10","author":"Adali","year":"2024","journal-title":"Heliyon"},{"key":"ref_72","unstructured":"Amano, K., Sano, T., Ide, T., Nakano, D., Tsutsumi, T., Arinaga-Hino, T., Kawaguchi, M., Hirai, S., Miyajima, I., and Torimura, T. (Intern. Med., 2025). Effect of MAFLD on hepatocarcinogenesis in HBeAg-negative patients with undetectable HBV-DNA under NA therapy: A multicenter study, Intern. Med., in press."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3350\/cmh.2022.0422","article-title":"Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives","volume":"29","author":"Huang","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Liu, C.H., Cheng, P.N., Fang, Y.J., Chen, C.Y., Kao, W.Y., Lin, C.L., Yang, S.S., Shih, Y.L., Peng, C.Y., and Chang, Y.P. (J. Hepatol., 2024). Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection, J. Hepatol., in press.","DOI":"10.1016\/j.jhep.2024.09.038"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12072-019-09939-2","article-title":"Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: A prospective, multicenter study","volume":"13","author":"Ide","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/hepr.13993","article-title":"Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study","volume":"54","author":"Sano","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-beta analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"82","author":"Ratziu","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): A multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","article-title":"A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis","volume":"5","author":"Harrison","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH with Fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and Efficacy of Efruxifermin in Combination with a GLP-1 Receptor Agonist in Patients with NASH\/MASH and Type 2 Diabetes in a Randomized Phase 2 Study","volume":"23","author":"Harrison","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/hepr.13706","article-title":"MAFLD: Renovation of clinical practice and disease awareness of fatty liver","volume":"52","author":"Kawaguchi","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1111\/liv.16016","article-title":"The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes","volume":"44","author":"Riley","year":"2024","journal-title":"Liver Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/hepr.14025","article-title":"Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease","volume":"54","author":"Tamaki","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/hepr.13678","article-title":"Evidence-based clinical practice guidelines for liver cirrhosis 2020","volume":"51","author":"Yoshiji","year":"2021","journal-title":"Hepatol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_91","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Mavrakanas, T.A., Tsoukas, M.A., Brophy, J.M., Sharma, A., and Gariani, K. (2023). SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: A systematic review and meta-analysis. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-42989-z"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Hou, Y.C., Zheng, C.M., Yen, T.H., and Lu, K.C. (2020). Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217833"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M., Iida, S., and Katsuyama, H. (2023). Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202309.1062.v1"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study","volume":"20","author":"Shibuya","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hepr.13236","article-title":"Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-021-01014-0","article-title":"Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial","volume":"12","author":"Seino","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin Improves the Hepatic Outcomes of Patients with Diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants with Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/dom.15548","article-title":"Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice","volume":"26","author":"Iwamoto","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s00535-024-02158-z","article-title":"Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: A nationwide database study in Japan","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J. Gastroenterol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1507\/endocrj.EJ24-0005","article-title":"Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: A retrospective analysis through magnetic resonance imaging","volume":"71","author":"Suzuki","year":"2024","journal-title":"Endocr. J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s40618-023-02246-6","article-title":"Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus","volume":"47","author":"Suzuki","year":"2024","journal-title":"J. Endocrinol. Investig."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.2147\/IJGM.S460200","article-title":"Evaluation of MASLD Fibrosis, FIB-4 and APRI Score in MASLD Combined with T2DM and MACCEs Receiving SGLT2 Inhibitors Treatment","volume":"17","author":"Liu","year":"2024","journal-title":"Int. J. Gen. Med."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Okura, T., Fujioka, Y., Nakamura, R., Kitao, S., Ito, Y., Anno, M., Matsumoto, K., Shoji, K., Matsuzawa, K., and Izawa, S. (2022). The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-05704-y"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/jdi.14226","article-title":"A multicenter, open-label, single-arm trial of the long-term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE-02)","volume":"15","author":"Hirota","year":"2024","journal-title":"J. Diabetes Investig."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13300-023-01526-x","article-title":"A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)","volume":"15","author":"Hirota","year":"2024","journal-title":"Diabetes Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00592-022-01981-1","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis","volume":"60","author":"Fakhrolmobasheri","year":"2023","journal-title":"Acta Diabetol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.2337\/diacare.23.12.1766","article-title":"Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients","volume":"23","author":"Taniguchi","year":"2000","journal-title":"Diabetes Care"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3803\/EnM.2022.1434","article-title":"The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018","volume":"37","author":"Bae","year":"2022","journal-title":"Endocrinol. Metab."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Niranjan, S., Phillips, B.E., and Giannoukakis, N. (2023). Uncoupling hepatic insulin resistance\u2014Hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1193373"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13098-015-0102-8","article-title":"Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus","volume":"7","author":"Qiang","year":"2015","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Honda, Y., Imajo, K., Kato, T., Kessoku, T., Ogawa, Y., Tomeno, W., Kato, S., Mawatari, H., Fujita, K., and Yoneda, M. (2016). The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146337"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s00535-024-02122-x","article-title":"Effects of luseogliflozin on suspected MASLD in patients with diabetes: A pooled meta-analysis of phase III clinical trials","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J. Gastroenterol."},{"key":"ref_117","first-page":"e45","article-title":"Sodium Glucose Cotransporter 2 Inhibition Combined with Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver","volume":"17","author":"Okada","year":"2018","journal-title":"Clin. Color. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/hepr.13247","article-title":"Spontaneous regression of hepatocellular carcinoma with reduction in angiogenesis-related cytokines after treatment with sodium-glucose cotransporter 2 inhibitor in a cirrhotic patient with diabetes mellitus","volume":"49","author":"Kawaguchi","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Nakachi, S., Okamoto, S., Tamaki, K., Nomura, I., Tomihama, M., Nishi, Y., Fukushima, T., Tanaka, Y., Morishima, S., and Imamura, M. (2022). Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans. Biomed. Pharmacother., 149.","DOI":"10.1016\/j.biopha.2022.112864"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/jgh.16498","article-title":"The impact of sodium-glucose cotransporter-2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer","volume":"39","author":"Chiang","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10120-024-01512-7","article-title":"Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: A population-based cohort study","volume":"27","author":"Chou","year":"2024","journal-title":"Gastric Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e237118","DOI":"10.6004\/jnccn.2023.7118","article-title":"Lower Risks of New-Onset Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus Treated with SGLT2 Inhibitors Versus DPP4 Inhibitors","volume":"22","author":"Chou","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jhbp.1391","article-title":"SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma","volume":"31","author":"Fujiyoshi","year":"2024","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/hepr.14081","article-title":"Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication","volume":"54","author":"Sakaue","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"101585","DOI":"10.1016\/j.diabet.2024.101585","article-title":"Association of SGLT2 inhibitors with incident cancer","volume":"50","author":"Suzuki","year":"2024","journal-title":"Diabetes Metab."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","article-title":"Cancer cell metabolism: Warburg and beyond","volume":"134","author":"Hsu","year":"2008","journal-title":"Cell"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol. Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"58353","DOI":"10.18632\/oncotarget.16874","article-title":"Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice","volume":"8","author":"Obara","year":"2017","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Shiba, K., Tsuchiya, K., Komiya, C., Miyachi, Y., Mori, K., Shimazu, N., Yamaguchi, S., Ogasawara, N., Katoh, M., and Itoh, M. (2018). Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-19658-7"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Nakano, D., Kawaguchi, T., Iwamoto, H., Hayakawa, M., Koga, H., and Torimura, T. (2020). Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232283"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","article-title":"Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"73","author":"Mao","year":"2024","journal-title":"Gut"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/HEP.0000000000000837","article-title":"Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: A Mendelian randomization and population-based cohort study","volume":"80","author":"Chung","year":"2024","journal-title":"Hepatology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Salybekov, A.A., Kobayashi, S., and Asahara, T. (2022). Characterization of Endothelial Progenitor Cell: Past, Present, and Future. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147697"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2007.03.110","article-title":"Significance and therapeutic potential of endothelial progenitor cell transplantation in a cirrhotic liver rat model","volume":"133","author":"Nakamura","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/jcp.22873","article-title":"Human peripheral blood CD34-positive cells enhance therapeutic regeneration of chronically injured liver in nude rats","volume":"227","author":"Nakamura","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.reth.2024.04.018","article-title":"Hepatic arterial infusion of autologous CD34(+) cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial","volume":"27","author":"Nakamura","year":"2024","journal-title":"Regen. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jcyt.2024.03.488","article-title":"Ex-vivo expanded CD34(+) cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice","volume":"26","author":"Masuda","year":"2024","journal-title":"Cytotherapy"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3350\/cmh.2021.0246","article-title":"Leaky gut-derived tumor necrosis factor-alpha causes sarcopenia in patients with liver cirrhosis","volume":"28","author":"Kawaguchi","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2739\/kurumemedj.MS6723009","article-title":"Subcutaneous Fat Thickness of the Lower Limb is Associated with Trunk Muscle Mass in Patients with Hepatocellular Carcinoma: A Simple Assessment for Sarcopenia Using Conventional Ultrasonography","volume":"67","author":"Sakai","year":"2022","journal-title":"Kurume Med. J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cld.2023.01.005","article-title":"Clinics in Liver Disease: Update on Nonalcoholic Steatohepatitis: Sarcopenia and Nonalcoholic Fatty Liver Disease","volume":"27","author":"Kawaguchi","year":"2023","journal-title":"Clin. Liver Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00535-011-0378-x","article-title":"Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: A pilot study","volume":"46","author":"Kawaguchi","year":"2011","journal-title":"J. Gastroenterol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1026070911202","article-title":"Searching for the exercise factor: Is IL-6 a candidate?","volume":"24","author":"Pedersen","year":"2003","journal-title":"J. Muscle Res. Cell Motil."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2739\/kurumemedj.MS674001","article-title":"The Effect of Walking Combined with Neuromuscular Electrical Stimulation on Liver Stiffness and Insulin Resistance in Patients with Non-alcoholic Fatty Liver Disease: An Exploratory Randomized Controlled Trial","volume":"67","author":"Iwanaga","year":"2023","journal-title":"Kurume Med. J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e0236","DOI":"10.1097\/HC9.0000000000000236","article-title":"Exercise changes the intrahepatic immune cell profile and inhibits the progression of nonalcoholic steatohepatitis in a mouse model","volume":"7","author":"Tsutsui","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/hepr.13670","article-title":"Effects of a low-intensity resistance exercise program on serum miR-630, miR-5703, and Fractalkine\/CX3CL1 expressions in subjects with No exercise habits: A preliminary study","volume":"51","author":"Hashida","year":"2021","journal-title":"Hepatol. Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/jgh3.12876","article-title":"A low-intensity 10-min resistance exercise program that ameliorated hepatic fibrosis indices and altered G-CSF\/IP-10\/PDGF-BB in a patient with nonalcoholic fatty liver disease: A case report","volume":"7","author":"Hashida","year":"2023","journal-title":"JGH Open"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00535-023-02060-0","article-title":"Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: A meta-analysis of randomized controlled trials","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J. Gastroenterol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1349-7006.2010.01521.x","article-title":"Insulin resistance and cancer: Epidemiological evidence","volume":"101","author":"Tsugane","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_152","first-page":"2355","article-title":"Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma","volume":"19","author":"Hashida","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Lee, J. (2020). Associations between Physical Activity and Liver Cancer Risks and Mortality: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17238943"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Kawaguchi, T., Yoshio, S., Sakamoto, Y., Hashida, R., Koya, S., Hirota, K., Nakano, D., Yamamura, S., Niizeki, T., and Matsuse, H. (2020). Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9040936"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/hepr.13667","article-title":"Myostatin as a fibroblast-activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma","volume":"51","author":"Yoshio","year":"2021","journal-title":"Hepatol. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.gt.3302959","article-title":"Gene therapy with CX3CL1\/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma","volume":"14","author":"Tang","year":"2007","journal-title":"Gene Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jso.20642","article-title":"Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma","volume":"95","author":"Matsubara","year":"2007","journal-title":"J. Surg. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/6\/428\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:53:02Z","timestamp":1760028782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/6\/428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":157,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cells14060428"],"URL":"https:\/\/doi.org\/10.3390\/cells14060428","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}